Evidence map›Paper›PMID 35493230›Full record

ArticleRSC advances2021

Synthesis of 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: a way forward for targeting hypoxia and drug resistance of cancer cells.

Galina I Buravchenko, Alexander M Scherbakov, Lyubov G Dezhenkova, Lianet Monzote, Andrey E Shchekotikhin

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Galina I BuravchenkoGause Institute of New Antibiotics 11 B. Pirogovskaya Street Moscow 119021 Russia shchekotikhin@mail.ru.
Alexander M ScherbakovBlokhin National Medical Research Center of Oncology 24 Kashirskoye Sh. Moscow 115522 Russia.ORCID https://orcid.org/0000-0002-2974-9555
Lyubov G DezhenkovaGause Institute of New Antibiotics 11 B. Pirogovskaya Street Moscow 119021 Russia shchekotikhin@mail.ru.
Lianet MonzoteDepartment of Parasitology, Pedro Kouri Tropical Medicine Institute Havana Cuba.
Andrey E ShchekotikhinGause Institute of New Antibiotics 11 B. Pirogovskaya Street Moscow 119021 Russia shchekotikhin@mail.ru.ORCID https://orcid.org/0000-0002-6595-0811
Gause Institute of New Antibiotics Russian Academy of Medical Sciences · RUD. Mendeleyev University of Chemical Technology of Russia · RUInstituto de Medicina Tropical “Pedro Kourí” · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To establish a new approach for the synthesis of quinoxaline 1,4-dioxides as hypoxia-selective cytotoxic agents, an original multi-step preparation of derivatives possessing the diamine moiety at position 7 was evaluated. Herein, we present the synthesis of a series of novel 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides 13a-h, 14a,b,g based on the regioselective Beirut reaction. Comparison of antitumor properties of derivatives possessing the diamine moiety at position 7 with structurally close congeners possessing the corresponding amino groups at position 6 revealed key differences in the cytotoxicity profiles and HIF-1α inhibition. All the synthesized 7-amino-6-halogeno derivatives 13a-h, 14a,b,g demonstrated significant cytotoxic activities against breast cancer cell lines (MCF7, MDA-MB-231) in normoxia and hypoxia with IC50 values ranging from 0.1 to 7.6 μM. Most of these novel derivatives can circumvent the multidrug resistance of tumor cells caused by P-glycoprotein over expression. The lead compounds 13a, 14a and 14b can suppress the expression of HIF-1α at low micromolar concentrations and induce apoptosis in breast cancer MCF7 cells. In addition, compound 14b effectively inhibits BCL2 and ERα expression in MCF7 cells. The current research opens a new direction for targeting hypoxia and drug resistance of cancer cells.

Identifiers

PMID35493230
PMCPMC9044171
OpenAlexW4205528304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.